Diebold Nixdorf, Incorporated (DBD) Stock Forecast
Data as of Oct 31, 2026Technology · Current price $55.50 (-6.15%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 13, 2026 | Matt Summerville | D.A. Davidson | $100.00 | +80.2% |
| Aug 7, 2025 | Antoine Legault | Wedbush | $70.00 | +26.1% |
| May 3, 2024 | Matt Bryson | Wedbush | $50.00 | -9.9% |
| Nov 10, 2023 | Matthew Summerville | D.A. Davidson | $29.00 | -47.7% |
| Jul 8, 2022 | Matt Bryson | Wedbush | $5.00 | -91.0% |
| Apr 30, 2022 | Matt Summerville | D.A. Davidson | $7.00 | -87.4% |
Top Analysts Covering DBD
DBD vs Sector & Market
| Metric | DBD | Technology Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.39 | 2.41 |
| Analyst Count | 4 | 14 | 19 |
| Target Upside | +80.2% | +3582.4% | +21.5% |
| P/E Ratio | 18.81 | 40.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.13B | $1.13B | $1.13B | 1 |
| 2027-03-31 | $887M | $890M | $891M | 1 |
| 2027-06-30 | $960M | $963M | $965M | 1 |
| 2027-09-30 | $1.00B | $1.00B | $1.01B | 1 |
| 2027-12-31 | $1.15B | $1.15B | $1.15B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.29 | $2.30 | $2.31 | 1 |
| 2027-03-31 | $1.02 | $1.02 | $1.03 | 1 |
| 2027-06-30 | $1.53 | $1.54 | $1.54 | 1 |
| 2027-09-30 | $1.77 | $1.77 | $1.78 | 1 |
| 2027-12-31 | $2.59 | $2.60 | $2.61 | 1 |
Frequently Asked Questions
What is the analyst consensus for DBD?
The consensus among 4 analysts covering Diebold Nixdorf, Incorporated (DBD) is Buy with an average price target of $100.00.
What is the highest price target for DBD?
The highest price target for DBD is $100.00, set by Matt Summerville at D.A. Davidson on 2026-02-13.
What is the lowest price target for DBD?
The lowest price target for DBD is $5.00, set by Matt Bryson at Wedbush on 2022-07-08.
How many analysts cover DBD?
4 analysts have issued ratings for Diebold Nixdorf, Incorporated in the past 12 months.
Is DBD a buy or sell right now?
Based on 4 analyst ratings, DBD has a consensus rating of Buy (2.00/5) with a +80.2% upside to the consensus target of $100.00.
What are the earnings estimates for DBD?
Analysts estimate DBD will report EPS of $2.30 for the period ending 2026-12-31, with revenue estimated at $1.13B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.